Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CDH2 Biologics Sequence Review Report 2026: Cadherin-2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDH2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD163 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M130 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD163 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD109 Biologics Sequence Review Report 2026: CD109 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD109 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LRIF1 Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor-interacting factor 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LRIF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
OGFR Biologics Sequence Review Report 2026: Opioid growth factor receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of OGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PIGR Biologics Sequence Review Report 2026: Polymeric immunoglobulin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of PIGR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD101 Biologics Sequence Review Report 2026: Immunoglobulin superfamily member 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD101 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LCORL Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor corepressor-like protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LCORL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IRAK2 Biologics Sequence Review Report 2026: Interleukin-1 receptor-associated kinase-like 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of IRAK2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LINGO1 Biologics Sequence Review Report 2026: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LINGO1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LINGO2 Biologics Sequence Review Report 2026: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LINGO2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IRAK1 Biologics Sequence Review Report 2026: Interleukin-1 receptor-associated kinase 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of IRAK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.